Buscar resultados de ensayos clínicos
Pharyngeal Diseases - 50 Studies Found
Estado | Estudiar |
Withdrawn |
Nombre del estudio: S9715, Chemotherapy and Radiation Therapy in Treating Patients With Advanced Cancer of the Nasopharynx Condición: Head and Neck Cancer Fecha: 1999-11-01 Intervenciones:
|
Not yet recruiting |
Nombre del estudio: A Study to Evaluate the Safety and Efficacy of Using the Combination Treatment of SHR-1210, Gemcitabine and Cis-platinum by Recurrent and Metastatic NPC Subjects Condición: Nasopharyngeal Carcinoma Fecha: 2017-04-13 Intervenciones:
|
Not yet recruiting |
Nombre del estudio: Measuring Patient-Reported Adverse Events in Oncology Practice Improves Quality of Life in Nasopharyngeal Carcinoma Condición: Nasopharyngeal Neoplasms Fecha: 2017-03-16 Intervenciones:
|
Not yet recruiting |
Nombre del estudio: Prospective Study for Molecular Biomarkers of Normal Nasopharyngeal Tissue Condición: Nasopharyngeal Carcinoma Fecha: 2017-01-19 |
Recruiting |
Nombre del estudio: High-activity Natural Killer Immunotherapy for Small Metastases of Nasopharyngeal Cancer Condición: Metastatic Nasopharyngeal Cancer Fecha: 2016-12-30 Intervenciones: Biological: High-activity natural killer Each treatment: 8~10 billion cells in all, transfuion in 3 time |
Not yet recruiting |
Nombre del estudio: A Study of Nasopharyngeal Carcinoma From Guangdong Condición: Nasopharyngeal Cancer Fecha: 2016-12-18 |
Recruiting |
Nombre del estudio: Chronomodulated Chemotherapy Followed by Concurrent Chemo-radiotherapy With IMRT in the Treatment of Advanced Nasopharyngeal Cancer Condición: Esophageal Neoplasms [C06.405.117.430] Fecha: 2016-08-16 Intervenciones:
|
Recruiting |
Nombre del estudio: A Trial of Endostar in Patients With Carcinoma of the Head and Neck Condición: Nasopharyngeal Neoplasms Fecha: 2016-08-12 Intervenciones: Drug: Endostar The patients will be randomized to CRT arm and CRT+Endostar arm. All patients will receiv |
Recruiting |
Nombre del estudio: Avelumab for Recurrent/Metastatic Nasopharyngeal Cancer Condición: Nasopharyngeal Cancer Fecha: 2016-08-18 Intervenciones: Drug: Avelumab Avelumab 10mg/kg IV on days 1 and 15 of each 28-day cycle. Treatment will be given until |
Active, not recruiting |
Nombre del estudio: A Study of ARGX-110 in Patients With Nasopharyngeal Carcinoma (NPC) Condición: Cancer Fecha: 2016-04-22 Intervenciones: Drug: ARGX-110 |